ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

Tripathy, D, Sara, T, Seidman, AD et al. (9 more authors) (2018) ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). In: Cancer Research. 2017 San Antonio Breast Cancer Symposium, 05-09 Dec 2017, San Antonio, Texas, U.S.A.. American Association for Cancer Research .

Metadata

Authors/Creators:
  • Tripathy, D
  • Sara, T
  • Seidman, AD
  • Anders, CK
  • Ibrahim, N
  • Rugo, HS
  • Twelves, CJ
  • Dieras, V
  • Mueller, V
  • Hannah, A
  • Tagliaferri, M
  • Cortes, J
Dates:
  • Published (online): 15 February 2018
  • Published: February 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Jul 2019 14:25
Last Modified: 11 Jul 2019 15:01
Status: Published
Publisher: American Association for Cancer Research
Identification Number: https://doi.org/10.1158/1538-7445.SABCS17-OT2-07-10
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)